Familial hypercholesterolemia evaluation in New York

Familial hypercholesterolemia, or FH, is an inherited condition that can cause high LDL from an early age. Healthy eating remains useful, but many people need medicine because diet alone cannot correct the inherited problem. FH affects the body’s ability to clear LDL. Heterozygous and homozygous forms differ in severity and treatment needs. Early identification matters because LDL exposure builds over time.

Diagnosis combines LDL results, untreated levels if known, family history of high cholesterol or early cardiovascular disease, examination, and sometimes genetic testing. Bring family and past-treatment records. Very severe or pediatric disease may need specialist care.

Not always. FH can be diagnosed from LDL levels and clinical and family history. Genetic testing may help confirm a diagnosis or guide family screening. An unavailable or negative result does not automatically exclude FH.

Children can have inherited high LDL and may need early assessment. Pediatric treatment uses age- and diagnosis-specific recommendations. Pediatric care may require a lipid specialist.

Cascade screening checks relatives after FH is identified in a family. It can use cholesterol testing and, when a relevant variant is known, genetic testing. The clinician or lipid team helps decide which relatives and tests are appropriate.

No. Treatment depends on LDL, cardiovascular risk, FH type when relevant, response, and tolerance of prior medicines. An injectable drug is one possible option, not a guaranteed result of the evaluation.

Bring dated cholesterol panels, all lipid medicines and doses tried, adverse effects, kidney or liver results, and family history of early heart disease. Include any genetic testing, prior heart attack or stroke records, and insurance denials. Outside records can help avoid repeating information.

Many forms of familial hypercholesterolemia affect LDL receptors, proteins on cell surfaces that help remove LDL cholesterol from the blood. Some LDLR gene changes reduce the number of receptors; others interfere with how they work. Changes in APOB, PCSK9 or LDLRAP1 can also disrupt this clearance pathway. The result is high blood LDL, not a diagnosis that every cell membrane has been physically damaged. Cholesterol can then accumulate in arteries and other tissues. The exact mechanism depends on the genetic form, and some people with a clinical FH diagnosis have no identified gene change.

Most common forms of familial hypercholesterolemia involving LDLR, APOB or PCSK9 are inherited in an autosomal dominant pattern: one altered gene copy can cause the condition. Less common LDLRAP1-related disease is autosomal recessive and requires two altered copies. Inheriting changes from both parents can produce severe disease, sometimes beginning in childhood. A genetic counselor or clinician can interpret the family’s results and arrange cholesterol testing for relatives; do not assume every FH family has the same inheritance pattern.